Tag: Roivant Sciences
Roivant Sciences, Pfizer create new business for inflammatory disease drug
Roivant Sciences, a US healthcare company, and Pfizer have established a new Vant to develop and commercialize PF-06480605 (now RVT-3101) for inflammatory and fibrotic bowel ... Read More
Roivant Sciences enters into $7.3bn merger with Montes Archimedes Acquisition
Roivant Sciences has agreed to merge with Montes Archimedes Acquisition (MAAC), a Nasdaq-listed special purpose acquisition company, in a deal that values the Swiss biopharma ... Read More
Roivant Sciences to acquire Silicon Therapeutics to boost drug discovery capabilities
Roivant Sciences has agreed to acquire Silicon Therapeutics, a Boston-based drug design, research, and development company, for $450 million, in an all-share deal. The Swiss ... Read More
Roivant launches Respivant Sciences to develop drugs for respiratory diseases
Roivant Sciences has launched a new biopharma company named Respivant Sciences which will focus on developing innovative therapeutics for serious respiratory diseases. The new biopharma ... Read More